Literature DB >> 10523836

Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity.

S Jaishankar1, J Zhang, M F Roussel, S J Baker.   

Abstract

In approximately 85% of Ewing sarcomas, chromosomal translocations give rise to the chimeric gene EWS/FLI, encoding the N-terminus of the RNA binding protein EWS fused to the DNA-binding domain of the ETS protein FLI-1. EWS/FLI is a stronger transcriptional activator than wild-type FLI-1, although both proteins bind to the same DNA sequences in vitro. In addition, EWS/FLI, but not FLI-1, is a transforming oncogene in NIH3T3 fibroblasts. EWS/FLI is thought to transform through its ability to deregulate the expression of target genes. We introduced several point mutations into the ETS domain of EWS/FLI that abolished DNA-binding activity. Although two of these mutations disrupted the transforming activity of EWS/FLI, one mutated protein containing a substitution of isoleucine 347 with glutamic acid (I347E) retained diminished transforming activity. In addition, EWS/FLI I347E did not activate expression of the endogenous EWS/FLI target gene manic fringe (MFNG). These studies demonstrate that a portion of the oncogenic activity of EWS/FLI is independent of FLI DNA-binding activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523836     DOI: 10.1038/sj.onc.1202940

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Functional cross-antagonism between transcription factors FLI-1 and EKLF.

Authors:  Joëlle Starck; Nathalie Cohet; Colette Gonnet; Sandrine Sarrazin; Zina Doubeikovskaia; Alexandre Doubeikovski; Alexis Verger; Martine Duterque-Coquillaud; François Morle
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

2.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

3.  The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts.

Authors:  Junhui Zou; Hitoshi Ichikawa; Michael L Blackburn; Hsien-Ming Hu; Anna Zielinska-Kwiatkowska; Qi Mei; Gerald J Roth; Howard A Chansky; Liu Yang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

5.  In vitro interaction between the N-terminus of the Ewing's sarcoma protein and the subunit of RNA polymerase II hsRPB7.

Authors:  Roumiana Todorova
Journal:  Mol Biol Rep       Date:  2008-07-08       Impact factor: 2.316

Review 6.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

Review 7.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

8.  TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins.

Authors:  L Yang; L J Embree; D D Hickstein
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

9.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Authors:  Aashi Chaturvedi; Laura M Hoffman; Alana L Welm; Stephen L Lessnick; Mary C Beckerle
Journal:  Genes Cancer       Date:  2012-02

10.  Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.

Authors:  Mukund Patel; Jeremy M Simon; Michael D Iglesia; Sam B Wu; Andrew W McFadden; Jason D Lieb; Ian J Davis
Journal:  Genome Res       Date:  2011-11-15       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.